The Pharmacy Times® Allergy resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Palforzia is an oral immunotherapy agent for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.
This generic drug product was determined by the FDA to be therapeutically equivalent to Adrenalin.
Two retail pharmacy case studies are presented.
Pharmacists should understand their mechanisms to facilitate high-quality, collaborative management with physicians.
Rx products features in the April 2020 issue.
Over-the-counter products featured in the April 2020 issue of Pharmacy Times.
Researchers have found that approximately 1% of children have an allergy to cow’s milk, but up to 14% of families believe their children may have the condition, pointing to official guidelines for detecting cow’s milk allergy as a possible cause for the overdiagnosis.
Aimmune’s peanut allergen power was approved by the FDA as an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut.
The FDA has approved olopatadine hydrochloride ophthalmic 0.1% and 0.2% solution for sale as an OTC medication in the United States.
The once-daily solution will be the first once-daily eye-itch allergy-relief drop to be available without a prescription in the United States.
Treatment with this peanut immunotherapy consists of 3 phases: Initial Dose Escalation, Up-Dosing, and Maintenance.
A pharmacy-driven assessment found more than half of patients with reported penicillin allergies were able to take antibiotics from the same drug class, rather than resorting to substitutes that may have downsides.